The U.S. Food and Drug Administration (FDA) has approved the inclusion of new evidence that Novartis Pharmaceuticals Corp.’s Cosentyx (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).1  The data will be added to the drug’s prescribing information and is effective in the U.S. immediately.…